What is the current CHM.AX stock price and market cap?

CHM.AX stock closed at **A$0.002** on 26 Feb 2026. Market capitalisation is approximately **A$8.84m** with **4,418,707,619** shares outstanding. Volume on the day was **59,797,051** shares.

Did CHM.AX report earnings today and what mattered?

Yes. The earnings announcement dated 26 Feb 2026 showed **EPS -0.01** and no operational profitability. Key items were R&D spend levels and cash per share, which frame runway and funding needs ahead of trial readouts.

What is Meyka AI's view and forecast for CHM.AX stock?

Meyka AI rates CHM.AX with a score out of 100: **65.87 | Grade B | HOLD**. Meyka AI's forecast model projects **A$0.006** in 12 months from the current **A$0.002**. Forecasts are model-based projections and not guarantees.

What are the main catalysts and risks for CHM.AX stock?

Primary catalysts are clinical readouts, partnerships, or licensing deals. Main risks include trial failure, cash runway constraints, dilution, and low liquidity given the small market cap.

AU Stocks

CHM.AX Chimeric Therapeutics (ASX) A$0.002 on 26 Feb 2026: earnings set catalysts

ByHuzaifa Zahoor February 26, 2026February 26, 2026

CHM.AX stock closed at A$0.002 on the ASX after Chimeric Therapeutics Limited released earnings details on 26 Feb 2026. We see a clinical-stage biotech still burning cash but holding meaningful trial assets. Today’s report confirms EPS of -0.01 and a market capitalisation near A$8.84m, keeping attention on upcoming trial readouts and funding needs. This earnings spotlight outlines key metrics, risks, and realistic price targets for investors.